Journal article
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer
GA Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, M Peeters, D Perez, BA Robinson, AH Strickland, T Ferguson, J Rodríguez, H Kröning, I Wolf, V Ganju, E Walpole, E Boucher, T Tichler, E Shacham-Shmueli, A Powell, P Eliadis Show all
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016
Abstract
Purpose: SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer. Patients and Methods: Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab. The primary end point was progression-free survival (PFS) at any site as assessed by independent centralized radi..
View full abstractGrants
Funding Acknowledgements
We thank all investigators in the SIRFLOX Study Group, and in particular the principal investigators. We acknowledge the editorial assistance provided by Martin Gilmour of ESP Bioscience (Crowthorne, United Kingdom) funded by Sirtex, during the preparation of this article.